These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of N-linked glycosylation on hemagglutinins derived from chicken embryos and MDCK cells: a case of the production of a trivalent seasonal influenza vaccine. Li J; Liu S; Gao Y; Tian S; Yang Y; Ma N Appl Microbiol Biotechnol; 2021 May; 105(9):3559-3572. PubMed ID: 33937925 [TBL] [Abstract][Full Text] [Related]
3. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Zost SJ; Parkhouse K; Gumina ME; Kim K; Diaz Perez S; Wilson PC; Treanor JJ; Sant AJ; Cobey S; Hensley SE Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12578-12583. PubMed ID: 29109276 [TBL] [Abstract][Full Text] [Related]
4. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines. Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263 [TBL] [Abstract][Full Text] [Related]
5. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies. Verma S; Soto J; Vasudevan A; Schmeisser F; Alvarado-Facundo E; Wang W; Weiss CD; Weir JP PLoS One; 2017; 12(4):e0175733. PubMed ID: 28423025 [TBL] [Abstract][Full Text] [Related]
6. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants. Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710 [TBL] [Abstract][Full Text] [Related]
7. Determination of the potency of a cell-based seasonal quadrivalent influenza vaccine using a purified primary liquid standard. Takahashi H; Fujimoto T; Horikoshi F; Uotani T; Okutani M; Shimasaki N; Hamamoto I; Odagiri T; Nobusawa E Biologicals; 2020 Nov; 68():32-39. PubMed ID: 33023810 [TBL] [Abstract][Full Text] [Related]
8. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China. Li C; Shao M; Cui X; Song Y; Li J; Yuan L; Fang H; Liang Z; Cyr TD; Li F; Li X; Wang J Biologicals; 2010 Mar; 38(2):284-9. PubMed ID: 20074976 [TBL] [Abstract][Full Text] [Related]
9. Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor. Chu C; Lugovtsev V; Lewis A; Betenbaugh M; Shiloach J Vaccine; 2010 Oct; 28(44):7193-201. PubMed ID: 20800699 [TBL] [Abstract][Full Text] [Related]
10. Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone. Medina J; Boukhebza H; De Saint Jean A; Sodoyer R; Legastelois I; Moste C Vaccine; 2015 Aug; 33(35):4221-7. PubMed ID: 26206270 [TBL] [Abstract][Full Text] [Related]
11. Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency. Khurana S; King LR; Manischewitz J; Coyle EM; Golding H Vaccine; 2014 Apr; 32(19):2188-97. PubMed ID: 24613520 [TBL] [Abstract][Full Text] [Related]
12. A Y161F Hemagglutinin Substitution Increases Thermostability and Improves Yields of 2009 H1N1 Influenza A Virus in Cells. Wen F; Li L; Zhao N; Chiang MJ; Xie H; Cooley J; Webby R; Wang PG; Wan XF J Virol; 2018 Jan; 92(2):. PubMed ID: 29118117 [TBL] [Abstract][Full Text] [Related]